ReShape Non Current Assets Total vs Other Stockholder Equity Analysis

RSLS Stock  USD 5.73  0.10  1.78%   
ReShape Lifesciences financial indicator trend analysis is much more than just breaking down ReShape Lifesciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ReShape Lifesciences is a good investment. Please check the relationship between ReShape Lifesciences Non Current Assets Total and its Other Stockholder Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Non Current Assets Total vs Other Stockholder Equity

Non Current Assets Total vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ReShape Lifesciences Non Current Assets Total account and Other Stockholder Equity. At this time, the significance of the direction appears to have weak relationship.
The correlation between ReShape Lifesciences' Non Current Assets Total and Other Stockholder Equity is 0.35. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of ReShape Lifesciences, assuming nothing else is changed. The correlation between historical values of ReShape Lifesciences' Non Current Assets Total and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of ReShape Lifesciences are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Non Current Assets Total i.e., ReShape Lifesciences' Non Current Assets Total and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.35
Relationship DirectionPositive 
Relationship StrengthVery Weak

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Other Stockholder Equity

Most indicators from ReShape Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.20 in 2024, whereas Tax Provision is likely to drop (36.8 K) in 2024.

ReShape Lifesciences fundamental ratios Correlations

0.97-0.130.73-0.030.340.570.08-0.360.150.23-0.30.340.210.920.37-0.180.210.250.120.440.040.17-0.310.260.23
0.97-0.130.8-0.090.310.37-0.06-0.470.00.21-0.320.270.210.90.42-0.190.20.190.090.340.020.15-0.230.260.18
-0.13-0.130.080.38-0.91-0.080.4-0.06-0.39-0.31-0.22-0.690.47-0.170.25-0.50.48-0.730.520.43-0.04-0.40.510.190.28
0.730.80.08-0.130.050.11-0.23-0.52-0.37-0.12-0.08-0.090.00.780.29-0.37-0.01-0.140.160.44-0.15-0.14-0.06-0.030.0
-0.03-0.090.38-0.13-0.370.220.320.31-0.12-0.04-0.57-0.440.72-0.310.18-0.050.72-0.380.640.32-0.16-0.07-0.170.660.22
0.340.31-0.910.05-0.370.24-0.310.00.390.360.140.76-0.370.35-0.10.4-0.370.78-0.43-0.250.110.44-0.51-0.17-0.17
0.570.37-0.080.110.220.240.530.240.620.18-0.070.420.10.490.0-0.020.10.350.170.590.110.13-0.410.110.26
0.08-0.060.4-0.230.32-0.310.53-0.150.31-0.170.14-0.110.180.09-0.10.110.18-0.170.180.54-0.08-0.230.250.030.68
-0.36-0.47-0.06-0.520.310.00.24-0.150.420.45-0.310.20.22-0.52-0.220.170.220.250.12-0.120.050.46-0.220.29-0.53
0.150.0-0.39-0.37-0.120.390.620.310.420.410.020.62-0.050.09-0.360.44-0.040.62-0.34-0.150.090.41-0.250.11-0.04
0.230.21-0.31-0.12-0.040.360.18-0.170.450.41-0.470.570.310.060.110.550.310.58-0.18-0.08-0.080.980.030.48-0.49
-0.3-0.32-0.22-0.08-0.570.14-0.070.14-0.310.02-0.470.2-0.920.08-0.50.06-0.930.19-0.490.050.08-0.40.23-0.950.07
0.340.27-0.69-0.09-0.440.760.42-0.110.20.620.570.2-0.380.4-0.190.39-0.380.96-0.57-0.090.340.56-0.21-0.18-0.3
0.210.210.470.00.72-0.370.10.180.22-0.050.31-0.92-0.38-0.160.47-0.071.0-0.360.60.11-0.160.24-0.030.940.15
0.920.9-0.170.78-0.310.350.490.09-0.520.090.060.080.4-0.160.19-0.19-0.160.3-0.080.490.060.02-0.14-0.120.21
0.370.420.250.290.18-0.10.0-0.1-0.22-0.360.11-0.5-0.190.470.19-0.430.45-0.310.40.090.360.02-0.30.370.27
-0.18-0.19-0.5-0.37-0.050.4-0.020.110.170.440.550.060.39-0.07-0.19-0.43-0.070.45-0.49-0.24-0.340.610.210.12-0.31
0.210.20.48-0.010.72-0.370.10.180.22-0.040.31-0.93-0.381.0-0.160.45-0.07-0.360.60.11-0.160.24-0.030.940.15
0.250.19-0.73-0.14-0.380.780.35-0.170.250.620.580.190.96-0.360.3-0.310.45-0.36-0.55-0.160.160.61-0.19-0.14-0.37
0.120.090.520.160.64-0.430.170.180.12-0.34-0.18-0.49-0.570.6-0.080.4-0.490.6-0.550.39-0.26-0.23-0.220.450.35
0.440.340.430.440.32-0.250.590.54-0.12-0.15-0.080.05-0.090.110.490.09-0.240.11-0.160.39-0.15-0.130.16-0.050.29
0.040.02-0.04-0.15-0.160.110.11-0.080.050.09-0.080.080.34-0.160.060.36-0.34-0.160.16-0.26-0.15-0.14-0.28-0.180.1
0.170.15-0.4-0.14-0.070.440.13-0.230.460.410.98-0.40.560.240.020.020.610.240.61-0.23-0.13-0.140.010.41-0.52
-0.31-0.230.51-0.06-0.17-0.51-0.410.25-0.22-0.250.030.23-0.21-0.03-0.14-0.30.21-0.03-0.19-0.220.16-0.280.01-0.16-0.12
0.260.260.19-0.030.66-0.170.110.030.290.110.48-0.95-0.180.94-0.120.370.120.94-0.140.45-0.05-0.180.41-0.160.01
0.230.180.280.00.22-0.170.260.68-0.53-0.04-0.490.07-0.30.150.210.27-0.310.15-0.370.350.290.1-0.52-0.120.01
Click cells to compare fundamentals

ReShape Lifesciences Account Relationship Matchups

ReShape Lifesciences fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets39.7M37.1M54.3M11.1M10.7M10.1M
Total Stockholder Equity24.1M14.5M46.1M3.7M6.7M6.3M
Retained Earnings(493.2M)(514.8M)(576.8M)(624.2M)(635.6M)(603.8M)
Other Assets99K46K1.5M102K117.3K111.4K
Common Stock Shares Outstanding31.4K26.0K3.8K7.3K102.7K128.9K
Liabilities And Stockholders Equity39.7M37.1M54.3M11.1M10.7M10.1M
Other Stockholder Equity517.3M529.4M622.4M627.9M642.3M323.4M
Total Liab15.6M22.6M8.2M7.5M4M3.8M
Short Long Term Debt Total3.0M9.5M279K171K262K248.9K
Other Current Liab5.6M7.2M3.2M5.1M1.8M3.3M
Total Current Liabilities10.4M11.6M7.3M7.5M3.8M6.0M
Property Plant And Equipment Net774K1.0M1.7M869K310K600.4K
Net Debt(2.2M)(2.5M)(22.5M)(3.7M)(4.2M)(4.4M)
Accounts Payable4.3M3.7M3.5M1.9M1.7M1.3M
Cash2.9M3.0M22.8M3.9M4.5M4.2M
Non Current Assets Total29.5M28.1M24.0M1.2M367K348.7K
Non Currrent Assets Other562.9K99K46K1.5M29K27.6K
Cash And Short Term Investments2.9M3.0M22.8M3.9M4.5M4.2M
Net Receivables4.1M2.6M2.8M2.2M1.7M997.2K
Non Current Liabilities Total5.2M11.0M855K2.6M223K211.9K
Other Current Assets1.7M1.1M1.4M265K437K415.2K
Property Plant And Equipment Gross774K1.0M1.7M1.2M400K618.1K
Total Current Assets10.1M8.9M30.3M9.9M10.3M16.2M
Accumulated Other Comprehensive Income(8K)(121K)(92K)(88K)(79.2K)(83.2K)
Short Term Debt291K314K558K342K222K210.9K
Common Stock8K6K18K1K23K21.9K
Property Plant Equipment16K584K1.7M869K782.1K565.6K
Other Liab6.2M4.7M1.6M855K983.3K934.1K
Current Deferred Revenue352K202K398K549K44K46.2K
Inventory1.3M2.2M3.0M3.6M3.7M3.9M
Net Tangible Assets(4.6M)(12.5M)25.2M3.4M3.1M4.0M
Retained Earnings Total Equity(334.8M)(419.0M)(493.2M)(514.8M)(463.3M)(486.5M)
Capital Surpluse410.8M450.6M517.3M529.4M608.8M386.1M
Deferred Long Term Liab5.3M1.8M702K615K707.3K929.9K
Intangible Assets28.7M27.0M20.8M260K299K284.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.